of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be con…

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be con…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 20, 2026, Anavex Life Sciences Corp. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Form 10-Q”), the Company is not in c…

Chief Operating Officer — Felix Lauscher: Felix Lauscher departed from the Company as part of a broader reorganization of duties.

Chief Executive Officer — Christopher Missling, PhD: Dr. Christopher Missling was terminated as CEO for cause due to conduct inconsistent with company policy.

Director — Axel Paeger, MD, MBA, MBI: Dr. Axel Paeger was appointed as a new independent director to fill a vacancy on the Board.

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be c…

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be c…

Entry into a Material Definitive Agreement. On July 25, 2025, Anavex Life Sciences Corp. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Sales Agent”). Pursuant to the Sales Agreement, the Company may offer and sell up to an aggregate offering price of $150,000,000 (the “Offering”) in shares of common stock, par value $0.001 per share (the “Shares”), from time to time through the Sales Agent. The issuance and sale of the Shares in the…

Chief Executive Officer — Christopher Missling, PhD: Dr. Christopher Missling's employment agreement was extended and his compensation terms were updated.

The filing describes an amendment to the equity incentive plan, not a management change.

of this Current Report, including Exhibit 99.1 attached hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be c…

Other Events. On February 7, 2023, Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”) filed a prospectus supplement with the Securities and Exchange Commission to the Company’s Shelf Registration Statement on Form S-3ASR (File No. 333-259788) registering shares of the Company’s common stock, par value $0.001 per share (the “Shares”), issuable pursuant to its purchase agreement dated February 3, 2023 with Lincoln Park Capital Fund, LLC (the “Purchase Agreement”). Snell & Wilmer…

Chief Executive Officer — Christopher Missling, PhD: The CEO's employment agreement was amended to extend the term and include increased compensation and performance-based stock options.

The filing details a compensation adjustment for the Principal Financial Officer.

Change in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm. On March 1, 2022, the Audit Committee (the “Audit Committee”) of the Board of Directors of Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”) dismissed BDO USA LLP (“BDO”) as the Company’s independent registered public accounting firm. The reports of BDO on the Company’s consolidated financial statements for each of the two most recently completed fiscal years did not…

Entry into a Material Definitive Agreement. On June 22, 2021, Anavex Life Sciences Corp. (the “Company”) and Deep Track Capital entered into a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell to Deep Track Capital an aggregate of 2,380,953 shares of common stock, par value $0.001 (the “Common Stock”), in a registered direct offering, for gross proceeds of approximately $50 million (the “Financing”). The purchase price for each share of Com…